Volume 6, Supplement 9SupplementAUA Guidelines and Their Impact on the Management of BPH: An UpdateSteven A KaplanBenign prostatic hyperplasiaMedical treatmentGuidelinesAmerican Urological AssociationSymptom score
Volume 6, Supplement 9SupplementThe Use of Nomograms for Selecting BPH Candidates for Dutasteride TherapyKevin M SlawinMichael W KattanBenign prostatic hyperplasiaNomogram5-reductase inhibitorsProgression
Volume 6, Supplement 9SupplementComparison of Clinical Trials With Finasteride and DutasterideJ Curtis NickelBenign prostatic hyperplasiaMedical therapyFinasterideDutasterideDihydrotestosterone5-reductase
Volume 6, Supplement 9SupplementThe Clinical Benefits of Dutasteride Treatment for LUTS and BPHClaus G RoehrbornBenign prostatic hyperplasiaLower urinary tract symptoms5-reductase inhibitorsDutasterideClinical trials
Volume 6, Supplement 9Supplement5-Alpha-Reductase: History and Clinical ImportanceLeonard S MarksBenign prostatic hyperplasiaFinasterideDutasterideDihydrotestosterone5-reductaseGuevedoces
Volume 6, Supplement 9SupplementPathophysiology, Epidemiology, and Natural History of Benign Prostatic HyperplasiaHerbert LeporBenign prostatic hyperplasiaLower urinary tract symptomsBladder outletobstructionAcute urinary retention
Volume 6, Supplement 9SupplementIntroduction: 5-Alpha-Reductase Inhibition in the Treatment of LUTS and BPH: Update and Importance of Dual Inhibition of Types 1 and 2Claus G Roehrborn
Volume 6, Supplement 10SupplementThe Future in Advanced Prostate Cancer: Take Your Partners or Is the Last Dance For Me?David I QuinnTargeted therapyResponse predictionHormonal agentsCytotoxic therapyRadiolabeled nucleotides
Volume 6, Supplement 10SupplementProstaScint Scan: Contemporary Use in Clinical PracticeSamir S TanejaProstate cancerStagingProstaScint
Volume 6, Supplement 10SupplementOverview of Prostate-Specific Membrane AntigenSam S ChangProstate cancerAngiogenesisProstate-specific membrane antigenMonoclonal antibody